Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Judge partly vacates convictions of opioid maker Insys' founder, executives

Published 11/26/2019, 09:05 PM
© Reuters. John Kapoor arrives at the federal courthouse in Boston

By Nate Raymond

BOSTON (Reuters) - A federal judge on Tuesday partially overturned the convictions of Insys Therapeutics Inc's founder and three former executives accused of bribing doctors to prescribe an addictive opioid, but declined to disturb the remainder of the jury's verdict.

U.S. District Judge Allison Burroughs in Boston ruled the evidence prosecutors presented at trial did not support finding that John Kapoor and the others intended for doctors to prescribe the drug, Subsys, to patients who did not need it.

The ruling could impact the eventual sentence received by Kapoor, the highest-ranking pharmaceutical executive to be convicted in a case tied to the deadly U.S. opioid addiction epidemic.

Chandler, Arizona-based Insys filed for bankruptcy in June days after striking a $225 million settlement with the U.S. Justice Department.

A federal jury found Kapoor, its onetime chairman, guilty in May of running a wide-ranging scheme to bribe doctors nationwide by retaining them to act as speakers at sham events ostensibly meant to educate clinicians about its fentanyl spray, Subsys.

But in her 85-page ruling, Burroughs said prosecutors failed to establish that Kapoor and his co-defendants intended for doctors to abdicate their duties to their patients and prescribed them Subsys for non-legitimate medical uses.

"Even though the evidence could be readily understood as proving that defendants did not care whether patients needed the drug, that still is not enough to prove the requisite intent," Burroughs wrote.

As a result, she vacated the convictions of Kapoor and three former executives, Richard Simon, Sunrise Lee and Joseph Rowan, for conspiring to illegally distribute a controlled substance and commit honest services fraud.

Those were some of the so-called predicate acts underlying their racketeering conspiracy conviction. She declined to overturn the related mail fraud and wire fraud convictions of those four and another former executive, Michael Gurry.

Burroughs said the evidence on those counts supported finding they carried out a scheme to bribe doctors and defraud insurers into paying for Subsys, which was approved only for treating pain in cancer patients.

Beth Wilkinson, Kapoor's lawyer, in a statement said: "We have always believed that the government brought charges it could not sustain."

She and other defense lawyers in court papers had claimed the illegal drug distribution charge if sustained could have resulted in longer prison sentences and Kapoor being sent to a prison reserved for "leaders and organizers in the drug-dealing world."

© Reuters. John Kapoor arrives at the federal courthouse in Boston

He and the others face sentencing in January.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.